Adding a specific urine-based tuberculosis screening test for persons living with HIV admitted to two hospitals in Africa decreased 56-day mortality among those with CD4 <100 cells/µL, severe anemia, or clinically suspected tuberculosis.
Decreasing tuberculosis (TB)-related mortality among people living with HIV (PLWH) is urgently needed. Tuberculosis diagnosis continues to be suboptimal, and many patients die before being diagnosed. In 2015, the World Health Organization endorsed the urine lipoarabinomannan assay (Alere Determine TB-LAM) for use in adults with HIV admitted to the hospital with signs and symptoms of TB and a CD4 count <100 cells/µL or severe illness. In this study, investigators in Malawi and South Africa assessed whether urine-based TB-LAM screening in PLWH improved TB outcomes. During a 2-year period, 4788 HIV-positive adults admitted to the hospital were screened for eligibility and about 2600 randomized (1300 to standard of care and 1300 to the interven…
Reviewing Author
DisclosuresGrant/Research SupportNIH/National Institute of Allergy and Infectious Diseases; NIH/National Institute on Drug Abuse
Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes; Vaccines
Leadership Positions in Professional SocietiesInternational Antiviral Society–USA (Board of Directors); Infectious Diseases Society of America (Past President)
DisclosuresGrant/Research SupportNIH/National Institute of Allergy and Infectious Diseases; NIH/National Institute on Drug Abuse
Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes; Vaccines
Leadership Positions in Professional SocietiesInternational Antiviral Society–USA (Board of Directors); Infectious Diseases Society of America (Past President)